Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > Action Reason...

<< Previous

Bullboard Posts

Next >>

Post by Maui527on Dec 22, 2021 9:12pm

460 Views

Post# 34256766

Action Reason...

Very clear that a significant short position needed to be closed prior to end of trading year and tax loss selling rules, hence today or tomorrow.

No material change to drive the increase other than the last 30 minutes of trading today. I see a pull back before January 4th.

After bthe 4th, we could see this start to move, but not at the rate that we witnessed today.

Cheers!

<< Previous

Bullboard Posts

Next >>

Paramount Resources signs $3.32 billion asset sale